Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Publication year range
1.
Pharm Dev Technol ; 26(6): 617-633, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33882793

ABSTRACT

Despite a relatively low prevalence of primary brain tumors, they continuously attract scientific interest because of the complexity of their treatment due to their location behind the blood-brain barrier. The main challenge in treatment of brain tumors is not the efficacy of the drugs, per se, but the low efficiency of drug delivery to malignant cells. At the core of the problem is the complex structure of the blood-brain barrier. Nowadays, there is evidence supporting the claim that bile acids have the ability to cross the blood-brain barrier. That ability can be exploited by taking a part in novel drug carrier designs. Bile acids represent a drug carrier system as a part of a mixed micelle composition, bilosomes and conjugates with various drugs. This review discusses the current knowledge related to bile acid molecules as drug penetration modifying agents, with the focus on central nervous system antitumor drug delivery.


Subject(s)
Antineoplastic Agents/metabolism , Bile Acids and Salts/metabolism , Blood-Brain Barrier/metabolism , Central Nervous System Agents/metabolism , Drug Delivery Systems/methods , Neoplasms/metabolism , Animals , Antineoplastic Agents/administration & dosage , Bile Acids and Salts/administration & dosage , Biological Transport/drug effects , Biological Transport/physiology , Blood-Brain Barrier/drug effects , Central Nervous System Agents/administration & dosage , Drug Carriers/administration & dosage , Drug Carriers/metabolism , Humans , Neoplasms/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL